Inari Medical Announces Interim Two-Year Results From The ClotTriever CLOUT Registry
Portfolio Pulse from Happy Mohamed
Inari Medical, Inc. (NASDAQ: NARI) announced positive two-year interim results from the CLOUT registry for its ClotTriever system, presented at the American Venous Forum. The results show excellent safety, effectiveness, and long-term outcomes in treating deep vein thrombosis (DVT), with significantly lower post-thrombotic syndrome (PTS) rates compared to historical studies. Inari's commitment to high-level research, including the DEFIANCE trial, aims to establish ClotTriever and FlowTriever systems as the standard of care for DVT and pulmonary embolism patients.
March 12, 2024 | 8:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inari Medical's positive interim results from the CLOUT registry highlight the ClotTriever system's safety and effectiveness in treating DVT, with lower PTS rates than historical studies. The company's commitment to research, including the DEFIANCE trial, underscores its aim to establish its systems as the standard of care for DVT and PE patients.
The positive interim results from the CLOUT registry demonstrate the ClotTriever system's effectiveness and safety, potentially increasing its adoption and usage in the treatment of DVT. This, combined with Inari Medical's commitment to further research through the DEFIANCE trial, could significantly enhance the company's reputation and market position in the medical device sector, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100